reninangiotensin
system
import
compon
cardiovascular
system
mount
evid
suggest
metabol
product
angiotensin
iiiniti
thought
biolog
inact
key
role
cardiovascular
physiolog
pathophysiolog
noncanon
axi
reninangiotensin
system
consist
angiotensin
angiotensin
angiotensinconvert
enzym
type
angiotensin
ii
receptor
r
protooncogen
ma
receptor
masrel
g
proteincoupl
receptor
member
compon
shown
counteract
effect
classic
reninangiotensin
system
counterregulatori
reninangiotensin
system
central
role
pathogenesi
develop
variou
cardiovascular
diseas
therefor
repres
potenti
therapeut
target
review
provid
latest
insight
complex
interplay
compon
noncanon
reninangiotensin
system
discuss
function
therapeut
potenti
target
system
treat
cardiovascular
diseas
reninangiotensin
system
ra
critic
role
cardiovascular
physiolog
effect
regu
late
blood
pressur
electrolyt
balanc
howev
pathophysiolog
condit
effect
ra
intensifi
trigger
inflamm
structur
remodel
thu
promot
cardiac
vascular
dam
age
research
studi
ra
centuri
understand
role
normal
physio
logic
function
also
develop
effect
therapi
treat
dysregul
systemat
research
effort
led
discoveri
non
canon
ra
challeng
hypothesi
ra
exert
deleteri
effect
cardiovascular
renal
system
classic
system
renin
cleav
angiotensinogen
form
angiotensin
sub
sequent
convert
angiotensin
ii
angiotensin
convert
enzym
ace
fig
convers
cleav
angiotensin
ii
produc
angiotensin
cleav
angiotensin
gener
angiotensin
increas
evid
support
concept
system
work
produc
opposit
effect
suggest
counter
balanc
role
two
axe
cardiovascu
lar
physiolog
diseas
timelin
key
histor
find
associ
studi
discoveri
counter
regulatori
ra
shown
box
light
emerg
multipl
studi
evalu
effect
signal
pathway
elicit
counter
regulatori
ra
past
decad
sought
provid
updat
current
understand
complex
regul
non
canon
ra
review
discuss
cardioprotect
effect
non
canon
ra
provid
critic
analysi
current
challeng
must
overcom
translat
therapeut
effect
clinic
context
counter
regulatori
ra
made
variou
pep
tide
receptor
enzym
fig
wherea
effect
angiotensin
angiotensin
cardio
vascular
system
explor
previous
potenti
role
counter
regulatori
ra
compo
nent
remain
poorli
understood
non
canon
ra
compon
includ
alamandin
angiotensin
angiotensin
well
angiotensin
angio
tensin
also
known
angiotensin
iii
iv
respect
figur
show
molecular
structur
peptid
past
year
new
evid
emerg
signal
pathway
trigger
counter
regulatori
ra
reveal
role
potenti
thera
peutic
target
cardiovascular
diseas
cvd
angiotensin
act
arrestinbias
agonist
type
angiotensin
ii
receptor
r
without
activ
ate
g
q
subunit
mechan
might
contribut
anti
hypertroph
properti
angiotensin
given
neither
activ
r
proto
oncogen
ma
receptor
antagonist
prevent
bene
ficial
effect
peptid
alamandin
activ
ampactiv
protein
kinas
ampk
nitric
oxid
pathway
via
ma
relat
g
protein
coupl
recep
tor
member
mrgd
prevent
angiotensin
ii
induc
hypertrophi
contrast
angiotensin
stimul
rakt
signal
pathway
pro
tect
myocardium
reperfus
induc
cell
death
moreov
angiotensin
shown
regul
intracellular
calcium
transient
left
ventri
cular
contractil
function
normal
rat
rat
heart
failur
hf
via
chymas
depend
cyclic
amp
depend
mechan
addit
angio
tensin
found
induc
atrial
natri
uret
peptid
anp
secret
isol
perfus
rat
atria
bind
ma
receptor
activ
pho
phatidylinositol
syn
thase
pathway
lastli
angiotensinogen
precursor
entir
ra
famili
peptid
date
studi
shown
angiotensinogen
elicit
direct
biolog
effect
heart
nonetheless
aryl
hydrocarbon
receptor
nuclear
transloc
like
protein
shown
modul
blood
pressur
mechan
involv
transcript
regul
angiotensinogen
circadian
manner
perivascu
lar
adipos
tissu
turn
increas
local
angio
tensin
ii
product
novel
find
shed
light
complex
regul
classic
ra
suggest
similar
complex
counter
regulatori
system
context
circadian
express
local
angiotensinogen
might
affect
organ
specif
activ
peptid
known
cardiovascular
effect
angiotensin
angiotensin
requir
investig
non
canon
ra
angiotensin
angio
tensin
bind
ma
receptor
r
respec
tive
wherea
alamandin
act
mrgd
fig
angiotensin
also
bind
mrgd
function
relev
associ
remain
unclear
emerg
evid
reveal
complex
interact
compon
classic
counter
regulatori
ra
initi
thought
given
angiotensin
also
shown
bind
r
moreov
r
form
heterodim
ma
receptor
inhibit
activ
r
use
radiolabel
dynam
mass
redistribut
experi
ment
cell
overexpress
ma
receptor
gaidarov
colleagu
found
although
angiotensin
antagon
angiotensin
ii
signal
angiotensin
bind
directli
ma
receptor
data
conflict
earlier
studi
demonstr
bind
fluoresc
label
angiotensin
ma
receptor
gaidarov
colleagu
note
absenc
ma
receptor
angiotensin
effect
angiotensin
ii
signal
howev
investig
also
reiter
rigor
control
experi
demonstr
interact
angiotensin
ma
receptor
scarc
moreov
given
find
suggest
angiotensin
bind
ma
receptor
research
hypoth
size
cardioprotect
effect
angiotensin
might
attribut
antagon
angio
tensin
ii
signal
nevertheless
addit
studi
requir
confirm
whether
angiotensin
endogen
agonist
ma
receptor
meem
colleagu
design
synthes
peptid
simultan
activ
ma
receptor
particul
guanylyl
cyclas
receptor
gener
fusion
angio
tensin
acid
sequenc
b
type
natriuret
peptid
bnp
reduc
blood
pressur
car
diac
unload
system
vascular
resist
exert
potent
natriuret
diuret
effect
separ
administr
bnp
angiotensin
observ
rais
possibl
fusion
counter
regulatori
ra
ligand
target
one
receptor
might
also
induc
synergist
effect
mediat
potent
cardioprotect
benefit
r
form
function
heterodim
ma
receptor
highlight
possibl
develop
drug
select
target
monom
oligom
upregul
downregul
specif
cell
signal
cascad
cardiovascular
system
addit
crystal
struc
ture
human
r
bound
select
ligand
indic
ligand
induc
activ
conform
receptor
suggest
r
bind
g
pro
tein
arrestin
tetzner
colleagu
show
angiotensin
bind
mrgd
r
antagonist
block
ma
receptor
mrgd
latter
find
particularli
import
given
larg
number
studi
utiliz
ing
assess
effect
r
activ
figur
provid
overview
signal
pathway
trigger
counter
regulatori
ra
ligand
upon
bind
receptor
ace
inhibitor
first
line
pharmacolog
therapi
manag
hypertens
proteas
neprilysin
also
known
neutral
endopeptidas
identifi
novel
therapeut
target
given
enzym
also
reduc
blood
pressur
might
reduc
blood
pressur
level
gener
angiotensin
angiotensin
ii
wherea
inhibit
neprilysin
increas
anp
level
addi
tion
endogen
metabol
regul
fibroblast
growth
factor
promot
genera
tion
adipocyt
renal
cell
therebi
promot
cleavag
angiotensin
ii
form
angiotensin
sug
gest
reduc
angiotensin
ii
induc
hypertens
chronic
activ
reninangiotensin
system
ra
promot
cardiovascular
damag
effect
antagon
compon
counterregulatori
ra
compon
counterregulatori
ra
includ
angiotensin
angiotensin
alamandin
receptor
found
protect
multipl
cardiovascular
diseas
hypertens
heart
failur
numer
preclin
studi
demonstr
benefici
effect
counterregulatori
ra
clinic
trial
confirm
observ
still
scarc
challeng
quantit
angiotensin
angiotensin
alamandin
associ
short
plasma
halflif
similar
molecular
structur
must
overcom
peptid
evalu
clinic
set
natur
review
cardiolog
fig
classic
counterregulatori
reninangiotensin
pathway
classic
system
renin
cleav
angiotensinogen
produc
angiotensin
peptid
process
angiotensinconvert
enzym
ace
form
angiotensin
ii
turn
bind
type
angiotensin
ii
receptor
r
r
r
activ
increas
aldosteron
antidiuret
hormon
adh
product
sympathet
nervou
system
sn
tone
blood
pressur
vasoconstrict
cardiac
hypertrophi
fibrosi
inflamm
vascular
smooth
muscl
cell
vsmc
dedifferenti
reactiv
oxygen
speci
ro
product
decreas
parasympathet
nervou
system
psn
tone
baroreflex
sensit
nitric
oxid
product
natriuresi
angiotensin
ii
process
aminopeptidas
apa
form
angiotensin
iii
also
act
r
angiotensin
iii
cleav
alanyl
aminopeptidas
n
apn
gener
angiotensin
iv
bind
r
produc
cardioprotect
effect
increas
natriuresi
product
well
reduc
vasoconstrict
inflamm
vsmc
dedifferenti
angiotensin
also
cleav
neprilysin
nep
produc
angiotensin
angiotensin
respect
angiotensin
activ
r
trigger
natriuresi
product
thu
mediat
vasodilatori
effect
reduc
blood
pressur
addit
peptid
cardioprotect
attenu
inflamm
cardiac
hypertrophi
fibrosi
angiotensin
bind
protooncogen
ma
receptor
masr
reduc
blood
pressur
noradrenalin
releas
hypertens
rodent
convers
activ
masr
increas
gener
natriuresi
vasodilat
psn
tone
baroreflex
sensit
angiotensin
also
form
angiotensin
ii
cleavag
metabol
alamandin
altern
angiotensin
ii
process
aspart
decarboxylas
ad
produc
angiotensin
convert
alamandin
upon
bind
masrel
g
proteincoupl
receptor
member
mrgd
alamandin
promot
effect
report
angiotensin
except
natriuresi
ra
reninangiotensin
system
classic
ra
act
local
system
level
signal
coordin
poorli
understood
exosom
extracellular
vesi
cle
nm
size
transport
transmit
molecul
protein
microrna
one
cell
anoth
also
transport
compon
classic
ra
previous
assum
scatter
cellular
wast
exosom
attract
much
research
interest
sinc
discoveri
role
intercellular
commun
consid
extracellular
vesicl
commun
signal
afar
counter
regulatori
ra
exert
effect
multipl
cell
type
vesicl
might
role
orchestrat
ing
effect
counter
regulatori
ra
context
pironti
colleagu
observ
exosom
induc
cardiac
pressur
overload
mice
contain
function
r
might
influenc
r
mediat
regul
vascular
tone
moreov
exosom
seem
role
local
ra
angiotensin
ii
trigger
exosom
product
rat
cardiac
fibroblast
vitro
exosom
turn
promot
angiotensin
ii
product
r
express
rat
cardiomyocyt
vitro
suggest
posit
feedback
mechan
might
contribut
exacerb
cardiac
hyper
trophi
elicit
angiotensin
ii
howev
evi
denc
support
role
exosom
orchestr
effect
canon
ra
whether
extracellular
vesicl
contribut
cardioprotect
properti
counter
regulatori
ra
remain
determin
receptor
axi
first
describ
receptor
sever
acut
respiratori
syndrom
coronaviru
character
mark
homolog
ace
therapeut
potenti
agonist
pulmonari
arteri
hypertens
pah
explor
number
studi
rat
monocrotalin
induc
pah
gene
therapi
prevent
pah
mediat
hypertrophi
function
impair
right
ventricl
moreov
synthet
activ
xnt
resorcinolnaphtha
lein
improv
pulmonari
arteri
endotheli
function
induc
phosphoryl
endotheli
syn
thase
dephosphoryl
consequ
increas
bioavail
meta
analysi
assess
efficaci
interven
tion
pah
reveal
synthet
activ
ator
among
potent
agent
although
find
strongli
support
therapeut
poten
tial
activ
translat
agent
clinic
set
remain
challeng
membran
bound
enzym
cleav
solubl
catalyt
activ
form
secret
given
increas
circul
level
timelin
figur
show
histor
perspect
import
find
associ
counterregulatori
reninangiotensin
system
ra
protooncogen
ma
receptor
masr
initi
describ
oncogen
detect
tumorigen
nude
mice
angiotensin
angiotensin
first
identifi
hydrolyt
cleavag
angiotensin
angiotensin
angiotensin
ii
respect
angiotensin
found
antihypertens
effect
rat
upon
unilater
inject
medial
nucleu
solitari
tract
dorsal
motor
nucleu
vagu
earliest
patent
relat
compon
counterregulatori
ra
describ
use
masr
assay
system
detect
angiotensinblock
activ
cdna
encod
type
angiotensin
ii
receptor
r
mice
rat
nucleic
acid
encod
angiotensin
cdna
encod
angiotensinconvert
enzym
use
angiotensin
prevent
revers
inhibit
reduc
cardiovascular
pulmonari
cerebr
renal
remodel
simultan
discov
two
independ
research
group
angiotensin
subsequ
describ
cardioprotect
peptid
antiinflammatori
action
found
activ
masr
first
clinic
trial
angiotensin
assess
effect
peptid
reduct
blood
flow
solid
tumour
wherea
first
trial
evalu
safeti
toler
recombin
form
antihypertroph
antihypertens
antiinflammatori
cardioprotect
properti
angiotensin
describ
alamandin
discov
antihypertens
agent
cardioprotect
properti
compound
sinc
describ
natur
review
cardiolog
might
therapeut
effect
recombin
human
develop
test
anim
model
administr
improv
right
ventricular
function
mice
subject
pressur
overload
attenu
vascular
remodel
mice
bleomycin
induc
pulmonari
hypertens
pilot
studi
evalu
effect
increas
enzi
matic
activ
intraven
infus
mgkg
mgkg
patient
pah
drug
well
toler
benefici
effect
pulmonari
vascular
resist
cardiac
output
addit
reduc
inflammatori
marker
increas
superoxid
dismutas
level
plasma
nonetheless
proof
ofconcept
studi
includ
five
patient
separ
studi
administr
also
shown
well
toler
patient
acut
respiratori
distress
syndrom
safeti
profil
need
assess
clinic
studi
angiotensin
ma
receptor
activ
might
also
protect
role
develop
ment
pah
notabl
howev
angiotensin
consid
good
therapeut
candid
owe
pharmacokinet
limit
angiotensin
rapidli
cleav
peptidas
thu
short
half
life
ref
howev
cell
signal
mechan
effect
mediat
biolog
peptid
thought
persist
despit
short
half
life
furthermor
stud
i
anim
model
shown
administr
angiotensin
includ
cyclodextrin
complex
neuroprotect
effect
improv
muscl
dam
age
induc
eccentr
cardiac
overload
stabl
cyclic
analogu
angiotensin
moder
reduc
right
ventricular
systol
pressur
rat
model
monocrotalin
induc
pah
signific
chang
observ
medial
wall
thick
pulmo
nari
arteriol
optim
protect
potenti
angiotensin
analogu
treatment
pah
compound
potenti
combin
neprilysin
inhibitor
activ
whether
approach
effect
maintain
high
level
angiotensin
requir
investig
r
stimul
r
activ
attenu
right
ventricular
pulmonari
remodel
r
stim
ulat
protect
mice
sever
lung
injuri
induc
sepsi
acid
aspir
wherea
r
defici
exacerb
hf
mice
subject
acut
myocardi
infarct
furthermor
activ
r
use
agonist
dkc
angiotensin
rat
model
chronic
lung
diseas
protect
heart
lung
adult
rat
pah
treat
angioten
sin
show
reduc
right
ventricular
weight
systol
pressur
well
diminish
lung
fibrosi
pulmonari
arteriol
thick
endotheli
damag
compar
untreat
control
effect
depend
activ
r
ma
receptor
treatment
angiotensin
also
reduc
plasma
level
pro
inflammatori
marker
tumour
necrosi
factor
tnf
cc
chemokin
ligand
also
known
mitogenactiv
protein
kinasephosphatas
result
attenu
cardiac
hypertrophi
r
also
activ
transcript
factor
promyelocyt
zinc
finger
protein
plzf
therebi
induc
express
ribosom
protein
kinas
express
turn
elicit
protein
synthesi
addit
r
might
trigger
vasodilat
activ
aktendotheli
nitric
oxid
synthas
eno
nitric
oxid
cgmp
pathway
either
via
angiotensin
activ
heterodimer
bradykinin
b
receptor
b
r
phosphoryl
akt
activ
r
angiotensin
bind
also
found
confer
cardioprotect
angiotensin
might
induc
nosolubl
guanylyl
cyclas
pathway
therebi
trigger
vasodilat
via
protooncogen
ma
receptor
masr
activ
activ
receptor
also
reduc
cardiac
fibrosi
stimul
dualspecif
phosphatas
dusp
consequ
inhibit
mitogenactiv
protein
kinas
mapk
k
ca
channel
mother
decantapleg
homologu
downstream
target
downregul
upon
masr
activ
addit
angiotensin
exert
antihypertroph
effect
inhibit
nuclear
factor
activ
cell
nfat
pathway
antihypertroph
effect
also
depend
atrial
natriuret
peptid
anp
secret
atrial
pace
associ
activ
na
h
exchang
calciumcalmodulindepend
protein
kinas
ii
camkii
via
pathway
cardiac
hypertrophi
also
reduc
activ
masrel
g
proteincoupl
receptor
member
mrgd
alamandin
via
adenyl
cyclas
ac
campprotein
kinas
pka
signal
activ
synthet
xnt
reduc
blood
pressur
angiotensin
ii
induc
model
hypertens
plasma
concentr
angiotensin
ii
angiotensin
remain
unal
tere
moreov
antihypertens
effect
drug
observ
mice
neither
xnt
dize
induc
enzymat
activ
rat
mous
kidney
find
rais
que
tion
whether
research
continu
focu
drug
unknown
mechan
action
howev
remain
appeal
therapeut
target
treat
hypertens
especi
tissu
express
enzym
higher
plasma
therapeut
potenti
dize
altern
treatment
hypertens
pah
shown
previou
experiment
studi
moreov
deoxycorticosteron
acet
doca
salt
hypertens
rat
treat
ma
receptor
agonist
lower
blood
pressur
level
untreat
control
anti
hypertroph
effect
part
mediat
inhibit
nadph
oxidas
nadph
oxidas
observ
hypertens
mice
subject
aortic
band
present
effect
activ
evalu
preclin
studi
rigor
evalu
ation
agent
exert
benefici
effect
need
test
clinic
set
order
identifi
target
potenti
toxic
effect
activ
also
assess
patient
high
blood
pressur
level
angio
tensin
ii
degrad
activ
monocyt
deriv
macro
phage
vitro
found
similar
cell
healthi
individu
patient
hyper
tension
note
activ
significantli
higher
monocyt
deriv
macrophag
patient
prehypertens
patient
hyper
tension
suggest
potenti
role
earli
marker
hypertens
find
might
also
indic
physiolog
protect
mechan
hypertens
probabl
rapid
degrad
angio
tensin
ii
contrast
correl
found
hypertens
activ
patient
st
segment
elev
myocardi
infarct
plasma
level
suggest
vari
depend
sex
although
research
explor
role
cvd
consid
sex
relat
differ
activ
level
preg
nanci
plasma
level
angiotensin
ii
significantli
elev
wherea
angiotensin
level
significantli
diminish
togeth
might
predispos
preg
nant
women
hypertens
relat
complic
furthermor
level
urinari
angiotensin
patient
hypertens
report
invers
proport
blood
pressur
level
impli
cru
cial
role
peptid
develop
hyper
tension
final
angiotensin
also
shown
allevi
obes
induc
haemodynam
alter
alamandin
alamandin
heptapeptid
form
catalyt
action
angiotensin
directli
angiotensin
heart
oral
admin
istrat
inclus
compound
alamandin
hydroxypropyl
cyclodextrin
reduc
blood
pressur
spontan
hypertens
rat
diminish
myocardi
fibrosi
isoprenalin
treat
rat
anti
hypertens
effect
shown
two
phase
initi
mean
arteri
pressur
left
ventricular
sy
tolic
pressur
increas
briefli
r
depend
manner
follow
reduct
paramet
persist
throughout
rest
infus
period
anti
hypertens
effect
revers
r
antagonist
addit
alaman
dine
treatment
mitig
vascular
remodel
mice
subject
transvers
aortic
constrict
addit
studi
requir
understand
complex
regul
alamandin
cell
signal
ling
cascad
trigger
therapeut
implica
tion
hypertens
cvd
normal
rang
alamandin
level
healthi
individu
patient
hypertens
establish
provid
better
understand
effect
ra
inhibit
alamandin
plasma
concentr
clinic
context
express
receptor
mice
lack
r
show
increas
respons
angiotensin
ii
significantli
elev
blood
pressur
level
wherea
transgen
overexpress
r
vascular
smooth
muscl
cell
mice
reduc
angiotensin
ii
induc
vasocon
striction
anti
hypertens
effect
r
select
agonist
angiotensin
also
evalu
treat
obes
rat
reduc
blood
pressur
level
compar
untreat
rat
associ
increas
urinari
sodium
excret
agonist
also
decreas
blood
pressur
level
spontan
hypertens
rat
prevent
endotheli
cell
migrat
mediat
vascular
endotheli
growth
factor
signal
specif
rho
kinas
inhibitor
fasudil
significantli
increas
plasma
level
angiotensin
motens
hypertens
rat
addit
fasudil
reduc
blood
pressur
level
aortic
rho
kinas
ace
activ
wherea
mrna
protein
level
increas
plasma
aortic
wall
interestingli
anoth
studi
show
increas
ace
angiotensin
ii
level
patient
high
risk
acut
pulmonari
embol
compar
healthi
volunt
moreov
rat
model
acut
pulmonari
embol
rhoarock
signal
mediat
imbal
ra
vasoconstrictor
revers
rock
inhibitor
activ
find
highlight
protect
effect
rock
inhibit
exert
set
hypertens
atherosclerosi
patholog
cardiovascular
remodel
studi
ocaranza
colleagu
administra
tion
angiotensin
reduc
blood
pressur
level
hypertens
rat
attenu
myocardi
damag
inhibit
develop
ventricular
hypertro
phi
fibrosi
importantli
effect
medi
ate
r
ma
receptor
signal
howev
separ
studi
gene
deliveri
angio
tensin
adeno
associ
viru
aav
mice
subject
coronari
arteri
ligat
complet
restor
wwwnaturecomnrcardio
systol
blood
pressur
level
cardiac
output
com
pare
sham
treat
mice
histolog
anali
si
reveal
mild
effect
cardiac
hypertrophi
fibrosi
notabl
ocaranza
colleagu
evalu
angiotensin
administr
week
compar
latter
studi
examin
effect
peptid
week
conflict
find
two
studi
suggest
attenu
myocardi
damag
might
transient
su
tain
long
term
howev
latter
studi
measur
plasma
level
angiotensin
aav
mediat
gene
deliveri
angiotensin
might
produc
therapeut
concentr
pep
tide
blood
would
suffici
protect
heart
advers
structur
remodel
studi
test
anti
hypertens
action
angiotensin
stroke
prone
spontan
hypertens
rat
also
found
evid
protect
effect
studi
use
dose
angiotensin
six
time
lower
use
ocaranza
colleagu
addit
studi
warrant
explor
anti
hypertens
anti
remodel
effect
angiotensin
admin
istrat
implic
plasma
level
peptid
cardioprotect
although
efficaci
angiotensin
administr
explor
clinic
set
patient
acut
respiratori
distress
syndrom
higher
angiotensin
level
plasma
associ
reduc
mortal
wherea
increas
plasma
angiotensin
level
associ
increas
mortal
heart
failur
critic
heart
function
vasodilat
fluid
balanc
mutant
mice
impair
con
tractil
increas
express
hypoxia
marker
increas
circul
level
angiotensin
ii
compar
control
mice
furthermor
mutant
mice
develop
angiotensin
ii
mediat
dilat
cardiomyopathi
character
increas
marker
oxida
tive
stress
inflamm
patholog
hypertrophi
impair
left
ventricular
function
interestingli
plasma
level
solubl
form
report
elev
patient
hf
reduc
eject
fraction
suggest
sustain
activ
counter
regulatori
ra
hf
might
compen
satori
mechan
attenu
cardiovascular
dysfunc
tion
mechan
underli
hf
preserv
eject
fraction
hfpef
remain
poorli
defin
progress
diseas
propos
link
hypertens
induc
cardiac
remodel
given
antihypertens
anti
remodel
effect
counterregulatori
ra
describ
thu
far
non
canon
signal
pathway
might
potenti
thera
peutic
target
treatment
hfpef
angiotensin
ii
infus
wild
type
mice
result
increas
blood
pressur
level
myocardi
hypertrophi
fibrosi
diastol
dysfunct
effect
exacerb
mice
convers
treatment
angiotensin
ii
infus
wild
type
mice
reduc
angio
tensin
ii
induc
superoxid
product
blunt
cardiac
hypertroph
respons
highlight
possibl
protect
role
enzym
hfpef
compon
non
canon
ra
path
way
also
involv
hf
mice
defici
alamandin
receptor
mrgd
left
ventricular
remodel
sever
dysfunct
present
pronounc
dilat
cardiomyopathi
furthermor
infus
r
agonist
day
rat
hf
induc
coronari
arteri
ligat
led
reduct
noradrenalin
excret
well
decreas
renal
sympathet
nerv
activ
addit
admin
istrat
increas
baroreflex
sensit
suggest
protect
role
drug
set
hf
collect
find
support
role
vari
ou
compon
counter
regulatori
ra
hf
potenti
biomark
therapeut
target
addit
clinic
studi
need
determin
level
angiotensin
angiotensin
patient
hf
role
non
canon
ra
signal
devel
opment
myocardi
infarct
describ
mrna
level
elev
set
myo
cardial
infarct
wherea
loss
exacerb
cardiac
damag
token
overexpress
shown
allevi
myocardi
damag
induc
ischaemiareperfus
rat
furthermor
administr
angiotensin
ad
oligosaccharid
hydroxypropyl
cyclodextrin
rat
myocardi
infarct
improv
cardiac
function
reduc
infarct
size
likewis
transgen
rat
overexpress
fusion
protein
lead
select
increas
angiotensin
level
less
suscept
reperfus
induc
arrhyth
mia
isoproterenol
induc
hypertrophi
wildtyp
rat
cardioprotect
role
r
prevent
post
ischaem
cardiac
remodel
document
mice
lack
r
aggrav
myocardi
infarct
induc
hf
reduc
surviv
compar
sham
treat
mice
correspondingli
transgen
mice
overexpress
r
show
improv
left
ven
tricular
function
myocardi
infarct
simi
lar
result
observ
rat
cardiac
specif
overexpress
r
administr
r
agonist
rat
subject
coronari
arteri
ligat
significantli
improv
recoveri
left
ventricular
func
tion
reduc
cardiac
remodel
myocardi
infarct
deliveri
angiotensin
aav
vector
mice
induct
myocardi
infarc
tion
result
reduct
sudden
cardiac
death
improv
left
ventricular
function
compar
con
trol
mice
importantli
angiotensin
posit
inotrop
effect
achiev
increas
calcium
transient
amplitud
contractil
protein
kinas
depend
mechan
use
ex
vivo
approach
isol
rat
heart
subject
global
ischa
mia
reperfus
mendoza
torr
colleagu
show
angiotensin
infus
also
reduc
infarct
size
apoptot
necrot
cell
death
improv
left
ventricular
function
r
depend
akt
depend
mechan
togeth
data
suggest
angiotensin
angiotensin
might
valuabl
pharmacolog
tool
treat
ment
myocardi
infarct
given
acut
long
term
cardioprotect
effect
inflammatori
process
central
develop
ment
progress
cvd
atherosclero
si
hypertens
myocardi
infarct
hf
link
inflamm
ra
previous
observ
cell
endogen
ra
regul
cell
function
nadph
oxidas
activ
superoxid
product
natur
killer
cell
also
shown
express
renin
angiotensinogen
ace
r
line
observ
pro
inflammatori
state
thought
upregul
ra
signal
ling
set
hypertens
interestingli
human
monocyt
also
express
ace
produc
angiotensin
angiotensin
taken
togeth
data
suggest
immun
system
might
also
involv
regul
non
canon
ra
activ
ma
receptor
shown
promot
anti
inflammatori
effect
mice
lack
receptor
exacerb
inflammatori
reaction
treatment
lipopolysaccharid
compar
wild
type
mice
therefor
ma
receptor
activ
might
valuabl
therapeut
target
counteract
pro
inflammatori
process
promot
develop
ment
progress
atherosclerosi
inde
ma
receptor
agonist
inhibit
atherogenesi
apo
mice
moreov
long
term
angiotensin
treatment
confer
vasoprotect
improv
endotheli
function
atheroprotect
reduc
lesion
progress
apo
mice
consist
observ
angiotensin
activ
signal
ling
pathway
critic
resolut
inflammatori
process
involv
asthma
addit
ma
receptor
r
signal
also
associ
regul
inflamma
tion
r
agonist
dose
depend
attenu
lipopolysaccharid
induc
tnf
product
increas
product
anti
inflammatori
cytokin
consist
observ
separ
studi
show
administr
prehypertens
obes
zucker
rat
reduc
plasma
level
tnf
wherea
coadministr
r
antagonist
decreas
level
kidney
furthermor
wistar
rat
subject
left
coronari
arteri
ligat
treatment
reduc
product
pro
inflammatori
cytokin
r
depend
manner
improv
systol
diastol
ventricular
function
reduc
scar
size
angiotensin
administr
also
shown
reduc
cardiac
renal
inflamm
docasalt
model
hypertens
rat
effect
independ
r
research
counter
regulatori
ra
result
gener
substanti
amount
intellectu
properti
relat
studi
use
current
pat
ent
applic
associ
system
file
relat
angiotensin
analogu
r
ma
receptor
angiotensin
patent
relat
cardiovascular
applica
tion
involv
control
arteri
pressur
vascular
remodel
cardiac
remodel
hf
furthermor
robust
evid
collat
larg
number
pre
clinic
studi
counter
regulatori
ra
also
prompt
initi
numer
clinic
trial
time
report
clinic
trial
involv
intervent
counter
regulatori
ra
molecul
cvd
ongo
includ
two
studi
design
evalu
safeti
recombin
angio
tensin
treat
thrombocytopenia
nine
trial
aim
assess
use
treatment
pulmonari
hypertens
safeti
use
angiotensin
hypoxia
hypertens
hf
coro
nari
arteri
bypass
surgeri
two
trial
investig
use
angiotensin
treat
peripher
arteri
diseas
obes
associ
hypertens
current
pre
recruit
phase
despit
substanti
amount
evid
suggest
counter
regulatori
role
non
canon
ra
protect
deleteri
action
dysregu
late
classic
ra
complex
relationship
two
system
remain
fulli
elucid
exampl
elev
patient
hf
pre
hypertens
depress
patient
pah
discrep
suggest
compon
counter
regulatori
ra
upregul
regul
depend
stage
sever
type
cvd
moreov
conflict
find
reinforc
lack
knowledg
physiolog
pathophysio
logic
mechan
involv
non
canon
ra
regul
instanc
elev
level
solubl
might
repres
compensatori
mechan
respons
hf
might
also
result
increas
cleav
age
membran
disintegrin
metallopro
teinas
domain
contain
protein
known
upregul
hf
addit
ra
peptid
also
modul
pharmacolog
treatment
regard
patient
chronic
hf
treat
ace
inhibitor
elev
plasma
level
angio
tensin
reduc
plasma
level
angio
tensin
ii
wherea
patient
acut
hf
treat
angio
tensin
ii
receptor
antagonist
decreas
plasma
level
angio
tensin
increas
plasma
level
angiotensin
ii
furthermor
addit
plasma
sampl
patient
hf
induc
convers
angiotensin
angiotensin
ii
angiotensin
angiotensin
respect
addit
aforement
challeng
inter
prete
data
non
canon
ra
measur
ment
angiotensin
angiotensin
alamandin
clinic
context
pose
mani
challeng
separa
tion
peptid
biolog
sampl
diffi
cult
given
similar
molecular
structur
angiotensin
two
amino
acid
shorter
angiotensin
wherea
angiotensin
alaman
dine
differ
n
termin
amino
acid
fig
therefor
identif
peptid
requir
use
high
precis
approach
high
perform
liquid
chromatographi
mass
spec
trometri
box
furthermor
one
fundament
problem
associ
use
peptid
clinic
context
short
plasma
half
life
owe
rapid
enzymat
degrad
numer
ongo
clinic
trial
assess
effect
angioten
sin
cvd
angiotensin
administ
via
subcutan
intraven
inject
howev
cycliz
angiotensin
analogu
describ
increas
half
life
improv
resist
enzi
matic
degrad
superior
function
activ
com
pare
natur
angiotensin
similar
chemic
modif
angiotensin
peptid
might
also
prolong
half
life
peptid
howev
non
peptid
agonist
half
life
h
also
induc
r
activ
agonist
high
select
receptor
well
toler
howev
although
result
date
promis
angiotensin
still
requir
extens
safeti
effi
caci
assess
potenti
endogen
r
agonist
oral
bioavail
agonist
also
report
modul
epi
genet
mechan
associ
pathophysio
logi
dia
betic
nephropathi
rais
possibl
unwant
target
effect
use
treat
cvd
studi
compar
ing
effect
angiotensin
use
establish
potenti
differ
two
agent
challeng
hinder
clinic
translat
counter
regulatori
ra
compon
treatment
cvd
overcom
therapeut
agent
might
use
complement
tradit
pharmacolog
ical
treatment
complementari
drug
nece
sari
even
gold
standard
drug
hypertens
associ
issu
suboptim
drug
effi
caci
adher
patient
hypertens
especi
comorbid
requir
two
drug
manag
blood
pressur
level
furthermor
mani
patient
requir
two
dose
day
suggest
separ
use
ace
inhibitor
angiotensin
ii
receptor
antagonist
alway
effect
use
one
drug
need
multipl
dose
per
day
increas
incid
advers
event
result
loss
adher
addit
longitudin
studi
evalu
dose
histori
patient
take
antihypertens
drug
found
nearli
half
patient
cohort
discontinu
treatment
result
poorli
control
hypertens
combin
counter
regulatori
ra
peptid
current
gold
standard
antihypertens
drug
one
pill
might
overcom
need
patient
hypertens
comorbid
receiv
one
drug
multipl
dosag
drug
per
day
counter
regulatori
ra
peptid
angiotensin
alamandin
angiotensin
found
effect
reduc
blood
pressur
attenu
cardiova
cular
remodel
preclin
studi
effect
might
achiev
fewer
advers
reaction
patient
hypertens
compar
current
antihypertens
therapi
turn
might
improv
treatment
adher
combin
angiotensin
angiotensin
receptor
blocker
losartan
might
increas
extend
blood
pressur
lower
capac
iti
importantli
anti
atherosclerot
effect
dual
angiotensin
losartan
therapi
synergist
pharmacolog
synergi
current
gold
standard
treatment
cvd
counter
regulatori
ra
pep
tide
might
decreas
dosag
requir
achiev
efficaci
therebi
reduc
advers
effect
howev
although
endogen
origin
counter
regulatori
ra
compon
suggest
safe
pharmacolog
pro
file
current
lack
robust
evid
patient
mean
hypothesi
remain
test
evid
support
protect
role
counter
regulatori
ra
cvd
robust
incom
plete
addit
methodolog
pitfal
must
overcom
futur
research
also
three
critic
issu
consid
ensur
method
quantifi
angiotensin
peptid
reliabl
first
sampl
procedur
must
effici
blood
tissu
sampl
need
undergo
immedi
peptidas
inhibit
ensur
stabil
angiotensin
metabolit
see
figur
part
sampl
durat
kept
short
possibl
avoid
unexpect
shift
angiotensin
metabolit
pattern
second
structur
similar
angiotensin
metabolit
fig
necessit
effect
separ
procedur
usual
liquid
chromatographi
peptid
separ
angiotensin
metabolit
quantifi
liquid
chromatographi
eluat
final
assay
must
sensit
given
angiotensin
metabolit
describ
level
femtomolar
rang
immunolog
assay
radioimmunoassay
ria
enzymelink
immunosorb
assay
elisa
mass
spectrometri
use
set
method
lower
limit
quantif
angiotensin
metabolit
fmolml
plasma
fmolg
tissu
sampl
although
ria
elisa
tradit
method
quantifi
angiotensin
peptid
given
high
sensit
specif
method
reli
heavili
characterist
antibodi
therefor
liquid
chromatographymass
spectrometri
promis
approach
obtain
reliabl
readout
given
capac
detect
reninangiotensin
system
ra
peptid
assess
uniqu
masstocharg
spectra
might
also
allow
measur
potenti
posttransl
modif
peptid
howev
techniqu
without
drawback
complex
spectrum
result
measur
multipl
compon
similar
masstocharg
ratio
report
moreov
approach
expens
requir
specif
expertis
consider
paramount
import
given
inaccur
measur
ra
peptid
lead
erron
conclus
might
cloud
understand
noncanon
ra
natur
review
cardiolog
conduct
larg
anim
high
translat
valu
confirm
data
studi
carri
vitro
small
anim
model
role
ra
peptid
angiotensin
iii
angiotensin
iv
cardiovascular
system
warrant
inv
tigat
furthermor
assess
classic
counter
regulatori
ra
peptid
routin
clin
ical
evalu
patient
cvd
con
sider
although
develop
practic
afford
accur
method
assess
level
requir
achiev
reliabl
readout
balanc
imbal
anc
level
peptid
plasma
urin
might
use
marker
cvd
moreov
thor
ough
evalu
counter
regulatori
ra
profil
patient
might
bring
current
therapeut
approach
step
closer
goal
precis
medicin
allow
tailor
treatment
plan
patient
optim
drug
efficaci
adher
publish
onlin
august
